Why Attend
The market value for cell therapies is expected to triple in size by 2025 to $8.21 bn, with investment also having increased by 64% since 2017 to $7.6 bn. Cell therapies have a huge commercial potential however scaled manufacturing, automation, logistics, regulation, and quality control continue to be limiting factors. Before cell therapies can make a mainstream clinical impact, patient access increased and truly reach their commercial potential, these obstructions need to be improved.
The Vein-to-Vein Congress will gather manufacturing, operations, site managers and logistical heads from both Biotechs and pharmaceutical companies to address these bottlenecks and facilitate the commercial manufacture of cell therapies.
As the cell therapy industry shifts from manual to automated manufacturing, the Vein-to-Vein Congress will discuss the measures that leading companies have put in place to streamline their manufacturing process, scale-up over time and ensure a water-tight supply chain with tracking and trackability from cell collection to patient.
The Speakers
Ali Mohamed
Markwin Velders
Dr David Sourdive, PhD
David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.
Emanuele Ostuni
Fabio Fachin
Niloofar Davoodi
Stefan Wildt
Liesbeth De Jong
Lior Raviv
Louise Bisset
Paul Kemp
Piers Walser
Qasim Rafiq
Volker Huppert
Jasmin Kee
Jean-Pierre Latere Dwan’Isa
Pierre Heimendinger
Sadia L'Bouch
Dr Detlev Parow
Cell Therapy Event Gallery
TESTIMONIALS
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
Past attendees include:
The Agenda
If you’re working on autologous or allogenic cell therapies, The Vein-to-Vein Congress will cover a diverse range of cell types including NK, CAR-T, stem and placental cells.
The global cell and gene therapy market is projected to surpass $35B by 2026 and with investment in the space increasing 64% in the last two years It’s obvious there’s huge commercial potential. The question is, with the cost of cell therapies at a premium, how can the industry reduce COGS and facilitate a mass role out? There are clear bottlenecks that exist across the industry; scale-up of manufacturing, logistics, raw material supply, regulation and automation of processes are all posing real headaches to the rapidly growing field.
The Vein-to-Vein Congress EU will focus on providing actionable solutions to these bottlenecks through case studies and interactive panel sessions with leaders in cell therapy who’ve been through the same challenges that you’re experiencing. Whether you’re streamlining logistics, scaling and automating manufacturing processes or developing robust raw material supply chains, join 100+ CTOs, COOs, Heads of Manufacturing, QC and Supply Chain who’ve been there and done just that.
Take away actionable insights from a range of cell therapy types including:
· Building an in-house cell therapy manufacturing facility with Markwin Velders of Kite Pharma
· Upscaling manufacturing for clinical and commercial manufacturing with Ali Mohamed of Immatics.
· Ensuring a reliable and traceable supply of quality GMP starting and raw material with David Sourdive of Cellectis.
· Streamlining cell therapy manufacture through automation and integration of instruments with Fabio Fachin of Takeda.
· Establishing end to end accountability of materials and product from vein to vein with Volker Huppert of Glycostem.
Download Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Expertise Partner
Miltenyi Biotec
Website: http://www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Innovation Partner
Fluidigm
Website: http://www.fluidigm.com
Fluidigm is committed to empowering the cancer immunotherapy community
with research tools to interrogate immune cell function and the tumor
microenvironment with unprecedented resolution.
Using proven mass cytometry and microfluidic technologies, we provide
workflows to identify and characterize changes in cellular phenotypes at
single-cell resolution. Whether you seek to target new biomarkers and
pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells
or cancer vaccines,
Fluidigm can help you identify new insights to reach your next research
breakthrough. Together we will transform the future of cancer care.
nanoString
Website: https://www.nanostring.com/
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The company is committed to offering tools that enable scientists and clinicians to translate today’s leading genomic research into clinically actionable tests that improve patient care. Gene expression panels for immune- oncology, autoimmunity, CAR-T and other applications are ready off the shelf tools offered to the Nanostring customers.
Event Partner
CellGenix
Website: http://www.cellgenix.com
CellGenix is a leading global supplier of high quality reagents and tools in the expanding market of cell and gene therapy and regenerative medicine.
As the first company to obtain a GMP manufacturing authorization for cell processing in Europe, CellGenix has more than 20 years of expertise in the development and GMP manufacturing of cell therapy products. Our products are used worldwide in clinical trials by academia and industry partners.
To ensure a seamless transition from research to commercialization we offer our customers a comprehensive product portfolio together with expert regulatory and technical support. Included in our product portfolio are cytokines, serum-free media and closed cell culture systems. Our products combine a maximum of quality and safety with excellent performance due to the state-of-the-art production, stringent in-house quality control and comprehensive documentation. All these factors help to simplify qualification and validation for your market authorization.
CellGenix operates a state-of-the-art GMP facility for production of recombinant proteins and cell processing in Freiburg, Germany. A subsidiary is located near Boston in Portsmouth, NH/USA.
Cell & Gene Therapy Catapult
Website: https://ct.catapult.org.uk/
Please visit our website for more information.Bio- Techne
Website: https://www.bio-techne.com/
The Bio-Techne family of brands offer a unique portfolio of high-quality reagents, instruments and services for life science researchers. To enable scientists working in the rapidly growing field of Targeted Protein Degradation, Bio-Techne provides a bespoke range of tools and reagents for the discovery, development and application of Degraders as well as custom services.
- Active Degraders and Degrader Building Blocks: The Tocris brand has pioneered commercialization of tool Degraders to make them available to the research community for investigating the phenotypic consequences of targeted protein knockdown. Tocris also supplies chemical building blocks (functionalized E3 ligase ligands plus linkers) to enable researchers to generate their own Degraders and offers custom synthesis of bespoke panels of Degrader Building Blocks.
- Ubiquitin Proteasome System (UPS) Proteins and Assays: Boston Biochem is the leading global provider of UPS related research products, with a catalog that includes UPS proteins, related antibodies and assay kits, as well as custom expertise in protein purification, characterization, modification, and assay development.
- Assays for Protein Degradation: Simple WesternTM systems from ProteinSimple, such as Wes™ and Jess, simplify and accelerate the detection of Degrader-mediated protein knockdown by automating the entire protein separation and detection process.
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
